August 5, 2026. Eli Lilly reported better-than-expected Q2 results and raised full-year guidance, but the stock's reaction told two opposite stories. LLY opened at 1177.50, ripped to 1215.94 within hours, then collapsed to 1148.61 by the close, erasing nearly the entire gain.
The fundamentals looked solid. Injectable GLP-1 products and the oral pill Foundayo drove earnings past estimates. Management lifted sales guidance, noting the company now treats nearly 10% of the US obesity population with GLP-1 therapies. That kind of market penetration should have sent the stock higher.
But sellers showed up above 1200. Buyers couldn't hold the line. By close, LLY had formed what traders call a rejection candle, opening near the high and closing near the low. The gap filled completely.
Momentum turned mixed fast. MACD crossed bearish at -2.07 versus a signal of 7.37. RSI14 sits neutral at 47.47. The stock now sits below the EMA20 at 1164.18 but still above the EMA50 at 1137.09 and well above the EMA200 at 1019.63.
For the bullish case to restart, LLY needs to reclaim the daily pivot at 1167.95 and hold above the EMA20. Without that, good earnings alone won't stop the pullback. The chart is saying buyers aren't convinced yet, even if the story is improving.
This material is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
